Ratings 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
4.435 ^USD	-1.00%		-10.04%	+3.86%

May. 08	Earnings Flash (TSVT) 2SEVENTY BIO Reports Q1 Revenue $12.4M, vs. Street Est of $14.1M	MT
May. 08	Transcript : 2seventy bio, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' opinions have been revised negatively.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
2SEVENTY BIO, INC.	+3.86%	228M	-
MODERNA, INC.	+23.37%	47.02B	B-
LONZA GROUP AG	+49.73%	41.86B	A
IQVIA HOLDINGS INC.	-0.94%	41.76B	B
CELLTRION, INC.	-4.32%	28.8B	C
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B	B
BIO-TECHNE CORPORATION	+3.20%	12.55B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B	C+
MEDPACE HOLDINGS, INC.	+30.23%	12.34B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes